SequelSEC

Contineum Therapeutics, Inc. CTNM

Pharmaceutical Preparations · CIK 0001855175 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2024-12-31
Operating income
-$17.05M
Fiscal year ended 2024-12-31
Free cash flow
-$10.37M
Fiscal year ended 2024-12-31

Contineum Therapeutics, Inc. (CTNM) reported revenue of $0 and net income of -$14.56M for the fiscal year ended 2024-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Contineum Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Contineum Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312024-09-302024-06-302023-12-312023-09-302023-06-30
Revenue$0$0$0$0$0$50.00M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$17.05M-$12.97M-$10.94M-$9.68M-$8.07M$38.94M
Net income-$14.56M-$10.27M-$9.01M-$7.77M-$6.25M$41.56M
Research & development$13.02M$9.73M$7.90M$8.01M$6.50M$9.46M
Weighted-average diluted sharesUnavailableshares 25.73Mshares 23.36MUnavailableshares 2.32Mshares 3.51M
Pretax income-$14.56M-$10.27M-$9.01M-$7.93M-$6.37M$42.29M
Income tax expense$0$0$0-$161.00K-$118.00K$729.00K
Diluted EPSUnavailable$-0.40$-0.39Unavailable$-2.69$0.84
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$4.03M$3.25M$3.04M$1.66M$1.57M$1.60M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Contineum Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312024-09-302024-06-302023-12-312023-09-302023-06-30
Cash & equivalents$21.94M$40.89M$77.23M$15.53MUnavailableUnavailable
Total assets$212.85M$216.03M$221.36M$130.39MUnavailableUnavailable
Current assets$206.39M$215.14M$220.32M$127.71MUnavailableUnavailable
Total liabilities$14.78M$5.81M$3.85M$5.70MUnavailableUnavailable
Current liabilities$9.97M$5.81M$3.74M$5.48MUnavailableUnavailable
Total equity incl. NCI$198.07M$210.23M$217.50M-$67.94M-$61.14M-$55.43M
Temporary (mezzanine) equity$0$0$0$192.62MUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.81M$1.40M$734.00K$635.00KUnavailableUnavailable

Cash flow

Contineum Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312024-09-302024-06-302023-12-312023-09-302023-06-30
Operating cash flow-$10.20M-$6.17MUnavailable-$10.70M-$5.38MUnavailable
Capital expenditures$166.00K$82.00KUnavailable$309.00K$22.00KUnavailable
Investing cash flow-$9.39M-$30.18MUnavailable$9.03M-$39.50MUnavailable
Financing cash flow$642.00K$13.00KUnavailable-$321.00K$10.32MUnavailable
Net change in cash-$18.95M-$36.34MUnavailable-$2.00M-$34.55MUnavailable
Stock-based compensation$2.25M$2.29MUnavailable$759.00K$477.00KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$75.00K$62.00KUnavailable$37.00K$43.00KUnavailable

Derived

Contineum Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312024-09-302024-06-302023-12-312023-09-302023-06-30
Free cash flow-$10.37M-$6.25MUnavailable-$11.01M-$5.40MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable77.9%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio20.69x37.06x58.92x23.29xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailable-100.0%UnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable18.9%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable1.7%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CTNM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.